---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-005810"
form_type: "8-K"
ticker: "UTHR"
cik: "0001082554"
company_name: "UNITED THERAPEUTICS Corp"
filed_at: "2026-01-22T23:59:59+00:00"
generated_at: "2026-05-16T08:40:31.026195+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# United Therapeutics appoints Kevin J. Tracey to board; bylaws amended to lower shareholder vote threshold

## Summary
- Kevin J. Tracey, M.D., appointed to board effective Jan 21, 2026; awarded 1,220 RSUs under director compensation plan.
- Bylaw amendments: create cure process for shareholder nomination deficiencies; lower shareholder vote to amend bylaws from 80% to majority.
- Tracey is President/CEO of Feinstein Institutes, co-founder of SetPoint Medical; brings expertise in inflammation and bioelectronic medicine.

## SEC filing metadata
- accession: 0001104659-26-005810
- form_type: 8-K
- ticker: UTHR
- cik: 0001082554
- company_name: UNITED THERAPEUTICS Corp
- filed_at: 2026-01-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1082554/000110465926005810/0001104659-26-005810-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1082554/000110465926005810/tm263500d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-005810
- JSON: https://secwatch.observer/filing/0001104659-26-005810.json
- Plain text: https://secwatch.observer/filing/0001104659-26-005810.txt

## Source-grounded claims
- claim_id: 10884d2bdbe4b525799ea83a2cd93158109f97c7
  claim: UNITED THERAPEUTICS Corp: Amended and restated bylaws to implement cure process for director nomination deficiencies, remove language allowing board to require supermajority vote, and lower stockholder vote required to amend bylaws from 80% to majority of voting power (effective 2026-01-21).
  evidence_excerpt: On January 21, 2026, the Board also approved amendments to, and the restatement of, the Company’s Tenth Amended and Restated Bylaws.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1082554/000110465926005810/0001104659-26-005810-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.